^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:carfilzomib (Proteasome inhibitor) +
    pomalidomide (TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Therapy for Previously Treated Multiple Myeloma:...The following regimens have been added for Bortezomib-Inhibitor Refractory, and Lenalidomide Refractory:...Carfilzomib/pomalidomide/dexamethasone...